Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)

Safety of Gadoterate Meglumine (Gd-DOTA) as a Contrast Agent for Magnetic Resonance Imaging

(2013) Tsuneo Ishiguchi et al.   Drugs in research & development

Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: Results in more than 84,000 patients

(2011) Martin Maurer et al.   EUROPEAN JOURNAL OF RADIOLOGY

Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines

(2011) Fulvio Stacul et al.   EUROPEAN RADIOLOGY

Risk of Acute Kidney Injury after Exposure to Gadolinium-Based Contrast in Patients with Renal Impairment

(2011) Chih-Chiang Chien et al.   RENAL FAILURE

Nephrogenic systemic fibrosis: Review of 408 biopsy-confirmed cases

(2011) Zhitong Zou et al.   INDIAN JOURNAL OF DERMATOLOGY

Contemporary Applications and Limitations of Magnetic Resonance Imaging Contrast Materials

(2009) Ricardo A. Natalin et al.   JOURNAL OF UROLOGY

Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency

(2009) Elena Ledneva et al.   RADIOLOGY

Frequency of Serum Creatinine Changes in the Absence of Iodinated Contrast Material: Implications for Studies of Contrast Nephrotoxicity

(2008) Jeffrey H. Newhouse et al.   AMERICAN JOURNAL OF ROENTGENOLOGY